<DOC>
	<DOCNO>NCT00621010</DOCNO>
	<brief_summary>This study first human exposure drug candidate CTS21166 healthy male volunteer</brief_summary>
	<brief_title>Safety Study CTS21166 Treat Alzheimer Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy adult male &gt; age 21 ; nonsmoker ( minimum 6 month ) ; History evidence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric , oncologic , allergic ( include anaphylactic drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease History evidence intravenous illicit drug use , human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C ; Participation another clinical trial within 30 day prior dose</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>